AR002069A1 - STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS. - Google Patents

STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS.

Info

Publication number
AR002069A1
AR002069A1 ARP960102657A AR10265796A AR002069A1 AR 002069 A1 AR002069 A1 AR 002069A1 AR P960102657 A ARP960102657 A AR P960102657A AR 10265796 A AR10265796 A AR 10265796A AR 002069 A1 AR002069 A1 AR 002069A1
Authority
AR
Argentina
Prior art keywords
stable
solutions
erythromicilamine
concentrated
erythromycylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ARP960102657A
Other languages
Spanish (es)
Inventor
Stefan Dr Leiner
Werner Dr Schleicher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica de C V SA filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of AR002069A1 publication Critical patent/AR002069A1/en
Anticipated expiration legal-status Critical
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una solución estable de eritromicilamina obtenida por disolución de la eritrocilamina en un medio acuoso tamponado a temperatura ambiente con valoresde pH entre 5 y 8 empleando preferentemente un sistema de tampón de fosfato. En estascondicione s la concentración de eritromicilamina puede estarcomprendida entre 5 y 40% en peso. La solución obtenida se esteriliza por filtración en condiciones asépticas. En estas condiciones las soluciones deeritromicilamina son estables ypueden emplea rse en medicina veterinaria en terapia e infecciones.A stable erythromycylamine solution obtained by dissolving erythrocylamine in a buffered aqueous medium at room temperature with pH values between 5 and 8, preferably using a phosphate buffer system. Under these conditions, the concentration of erythromycylamine can be between 5 and 40% by weight. The obtained solution is sterilized by filtration under aseptic conditions. Under these conditions, the erythromycylamine solutions are stable and can be used in veterinary medicine for therapy and infections.

ARP960102657A 1995-05-23 1996-05-22 STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS. Withdrawn AR002069A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19518917A DE19518917A1 (en) 1995-05-23 1995-05-23 Stable, concentrated, locally tolerated erythromycylamine solutions

Publications (1)

Publication Number Publication Date
AR002069A1 true AR002069A1 (en) 1998-01-07

Family

ID=7762671

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102657A Withdrawn AR002069A1 (en) 1995-05-23 1996-05-22 STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS.

Country Status (6)

Country Link
AR (1) AR002069A1 (en)
AU (1) AU5898296A (en)
DE (1) DE19518917A1 (en)
IL (1) IL118381A0 (en)
WO (1) WO1996037190A1 (en)
ZA (1) ZA964082B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723447A (en) * 1996-07-02 1998-03-03 Rhone Merieux, Inc. Water miscible erythromycin solutions
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA695765B (en) * 1968-08-29 1971-03-31 Lilly Co Eli Erythromycylamine and process for preparing same
ZA71763B (en) * 1970-04-13 1972-03-29 Lilly Industries Ltd Erythromycylamines via hydrazones
IL81395A0 (en) * 1986-02-03 1987-08-31 Lilly Co Eli Novel derivatives of erythromycylamine
US5110800A (en) * 1986-02-18 1992-05-05 Eli Lilly And Company Derivatives of erythromycylamine
DE4410637C1 (en) * 1994-03-26 1995-09-21 Boehringer Ingelheim Vetmed Injectable solutions of dirithromycin

Also Published As

Publication number Publication date
AU5898296A (en) 1996-12-11
IL118381A0 (en) 1996-09-12
ZA964082B (en) 1996-11-22
DE19518917A1 (en) 1996-11-28
WO1996037190A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
ES2097802T3 (en) HISTIDINE BUFFER SOLUTION FOR PERITONEAL DIALYSIS.
BG102708A (en) 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
ATE226085T1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING NERVE GROWTH FACTOR
DK0633721T3 (en) Platelet purification with the 8-methoxypsoralen
BR9702362A (en) New stable liquid formulas based on paracetamol and its preparation.
ES2032563T3 (en) A METHOD TO PRODUCE A FREEZE PHARMACEUTICAL COMPOSITION OF SMANCS.
IL86211A (en) Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
ES2108592T3 (en) THICKENED COMPOSITION IN AQUEOUS MEDIUM AND THICKENING PROCEDURE OF A WATERY MEDIA.
TR199701294T1 (en) Composition consisting of amoxicillin and clavulanic acid.
ES2162913T3 (en) PHARMACEUTICAL PREPARATION CONTAINING PLASMINOGEN ACTIVATORS.
ATE95564T1 (en) OUTER MEMBRANE PROTEIN F OF PSEUDOMONAS AERUGINOSA.
AR002069A1 (en) STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS.
ES2183417T3 (en) CONCENTRATED FOR MEDICAL SOLUTION AND ITS USE.
AU5684286A (en) Use of an aqueous, stabilised chlorite matrix solution for infectious conditions
ES2067520T3 (en) ANTIBIOTICS AND PROCEDURE FOR ITS PRODUCTION.
FR2577048B1 (en) REAGENT FOR THE HEMAGGLUTINATION DETERMINATION OF ANTIBODIES AGAINST BACTERIAL TOXINS, METHOD OF PREPARATION AND ITS APPLICATION
DE3862017D1 (en) PHARMACEUTICAL PREPARATION FOR TINEA PEDIS TREATMENT.
HUP0302310A2 (en) Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone and process for their preparation
BR9611588A (en) Use of flupirtine in the prophylaxis and therapy of diseases associated with damage to the hematopoietic cellular system
IT1226072B (en) READY TO USE INJECTABLE SOLUTIONS CONTAINING AN ANTI-CYCLINIC ANTI-TUMORAL GLYCOSIDE.
DK0402806T3 (en) Crystalline cephemic acid addition salts and process for their preparation
ES2091764T3 (en) WATER PURIFICATION SYSTEM.
ES2122962T3 (en) OPTICALLY ACTIVE ALKYLENE-DIOXYBENZENE DERIVATIVES AND THEIR USE IN THERAPY.
DE69613803D1 (en) Eye drops especially for the treatment of dry eyes
NZ235297A (en) Aqueous solution containing a protein and anionic polymer or salt and method of increasing the protein concentration of an aqueous solution

Legal Events

Date Code Title Description
FA Abandonment or withdrawal